Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Non-Current Assets (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Other Non-Current Assets for 10 consecutive years, with $60.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets fell 4.76% to $60.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $60.0 million, a 4.76% decrease, with the full-year FY2025 number at $60.0 million, down 4.76% from a year prior.
  • Other Non-Current Assets was $60.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $57.9 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $63.0 million in Q4 2024 to a low of $8.9 million in Q1 2021.
  • A 5-year average of $38.6 million and a median of $38.1 million in 2022 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 222.45% in 2021, then decreased 4.76% in 2025.
  • Ultragenyx Pharmaceutical's Other Non-Current Assets stood at $20.6 million in 2021, then skyrocketed by 135.13% to $48.3 million in 2022, then increased by 19.34% to $57.7 million in 2023, then increased by 9.21% to $63.0 million in 2024, then fell by 4.76% to $60.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Other Non-Current Assets are $60.0 million (Q4 2025), $57.9 million (Q3 2025), and $60.1 million (Q2 2025).